GeneHealth - Your precision medicine

Calciphylaxis

Disease Details

Family Health Simplified

Buy Membership

Description: Calciphylaxis is a rare, serious condition characterized by the calcification of blood vessels in the skin and fat tissue, leading to painful skin ulcers and an increased risk of infection.
Type: Calciphylaxis is not primarily a genetic disease. It is a rare and serious condition often associated with chronic kidney disease and disturbed calcium-phosphorus metabolism. It involves the calcification of small blood vessels, leading to tissue necrosis. Its exact cause is unknown, but it is generally not considered to be inherited in a simple genetic manner.
Signs And Symptoms: The first skin changes in calciphylaxis lesions are mottling of the skin and induration in a livedo reticularis pattern. As tissue thrombosis and infarction occurs, a black, leathery eschar in an ulcer with adherent black slough develops. Surrounding the ulcers is usually a plate-like area of indurated skin. These lesions are always extremely painful and most often occur on the lower extremities, abdomen, buttocks, and penis. Lesions are also commonly multiple and bilateral. Because the tissue has infarcted, wound healing seldom occurs, and ulcers are more likely to become secondarily infected. Many cases of calciphylaxis lead to systemic bacterial infection and death.Calciphylaxis is characterized by the following histologic findings:

systemic medial calcification of the arteries, i.e. calcification of tunica media. Unlike other forms of vascular calcifications (e.g., intimal, medial, valvular), calciphylaxis is characterized also by
small vessel mural calcification with or without endovascular fibrosis, extravascular calcification and vascular thrombosis, leading to tissue ischemia (including skin ischemia and, hence, skin necrosis).
Prognosis: Overall, the clinical prognosis for calciphylaxis is poor. The 1-year mortality rate in patients who have end-stage kidney disease is 45-80%. Median survival in patients who do not have end-stage kidney disease is 4.2 months. Response to treatment is not guaranteed. The most common cause of death in calciphylaxis patients is sepsis, severe infection originating from a non-healing ulcer.
Onset: Calciphylaxis, also known as calcific uremic arteriolopathy, typically has a gradual onset. It commonly affects patients with advanced chronic kidney disease, particularly those on dialysis. Symptoms may develop over weeks to months and include painful skin lesions, necrosis, and ulcerations. Prompt medical attention is crucial.
Prevalence: The prevalence of calciphylaxis is not precisely known but it is considered a rare condition. Estimates suggest it affects 1-4% of patients with end-stage renal disease (ESRD) on dialysis.
Epidemiology: Calciphylaxis most commonly occurs in patients with end-stage renal disease who are on hemodialysis or who have recently received a kidney transplant. When reported in patients without end-stage renal disease (such as in earlier stages of chronic kidney disease or in normal kidney function), it is called non-uremic calciphylaxis by Nigwekar et al. Non-uremic calciphylaxis has been observed in patients with primary hyperparathyroidism, breast cancer (treated with chemotherapy), liver cirrhosis (due to hazardous alcohol use), cholangiocarcinoma, Crohn's disease, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE). Calciphylaxis, regardless of etiology, has been reported at an incidence of 35 in 10,000 dialysis patients per year in the United States, 4 in 10,000 patients in Germany, and less than 1 in 10,000 patients in Japan. It is unknown whether the higher incidence in the United States is due to genuinely higher incidence or due to underreporting in other countries. Annual incidence in kidney transplant patients and in non-uremic calciphylaxis patients is also unknown. The median age of patients at diagnosis of calciphylaxis is 60 years and the majority of these patients are women (60-70%). The location of lesions, central (located on the trunk) or peripheral (located on the extremities), is dependent on several risk factors. Central lesions are associated with younger patients, patients with a higher body mass index, and a higher risk of death than those who have peripheral-only lesions.
Intractability: Yes, calciphylaxis is often considered intractable due to its severe nature and resistance to many treatments. It is a rare and serious condition typically seen in patients with end-stage renal disease and is characterized by painful skin ulcers and a high risk of infection. The management is challenging, and response to treatment can be limited, making it difficult to control and leading to a high mortality rate.
Disease Severity: Calciphylaxis is a serious and often fatal condition. It involves the calcification of small and medium-sized blood vessels, leading to painful skin ulcers and systemic complications. The disease severity is high, and early diagnosis and aggressive treatment are critical.
Healthcare Professionals: Disease Ontology ID - DOID:4734
Pathophysiology: Calciphylaxis is a rare and serious condition primarily affecting individuals with end-stage renal disease.

**Pathophysiology:**
1. **Vascular Calcification:** This involves calcium deposition in the small and medium-sized blood vessels, particularly cutaneous and subcutaneous adipose tissues.
2. **Thrombosis:** The calcified vessels lead to thrombosis, reducing blood flow to tissues.
3. **Tissue Necrosis:** The compromised blood flow results in ischemia and necrosis of the skin and underlying tissues.
4. **Risk Factors:** Include chronic kidney disease, hyperparathyroidism, diabetes, obesity, and certain medications like warfarin.
5. **Calcium-Phosphate Imbalance:** Elevated serum phosphate and dysregulated calcium-phosphate metabolism contribute significantly to vascular calcification.

Understanding its pathophysiology is crucial for developing targeted treatment strategies and minimizing the risk factors associated with this condition.
Carrier Status: Calciphylaxis does not have a carrier status, as it is not a genetic condition or infectious disease. It is a serious, uncommon disease characterized by calcification of small blood vessels in fat and skin tissues, leading to painful skin ulcers and can be life-threatening. It often occurs in individuals with end-stage kidney disease or severe hyperparathyroidism.
Mechanism: Calciphylaxis, also known as calcific uremic arteriolopathy, is a rare and serious condition often seen in patients with end-stage renal disease (ESRD) and those on dialysis. It involves calcification and thrombosis of small blood vessels, leading to necrosis of the skin and other tissues.

### Mechanism
1. **Vascular Calcification**: The process begins with the deposition of calcium in the small arterioles of the dermis and subcutaneous fat.
2. **Thrombosis**: This calcification leads to the narrowing of these vessels, causing significant ischemia and, eventually, cutaneous necrosis.
3. **Inflammation**: Inflammatory processes exacerbate vascular injury and subsequent tissue necrosis.
4. **Tissue Necrosis**: Without adequate blood supply, the affected skin and subcutaneous tissue undergo necrosis, manifesting as painful skin ulcers and necrotic patches.

### Molecular Mechanisms
1. **Dysregulation of Mineral Metabolism**: Imbalances in calcium and phosphate homeostasis are central. Elevated phosphate levels promote vascular smooth muscle cell (VSMC) transformation into osteoblast-like cells that promote calcification.
2. **Role of Vitamin K**: Deficiency in Vitamin K can impair the function of matrix Gla protein, a potent inhibitor of vascular calcification, thereby promoting the process.
3. **Hyperparathyroidism**: Secondary hyperparathyroidism, common in ESRD patients, can lead to extra-skeletal calcification due to the pathological increase in parathyroid hormone (PTH).
4. **Inflammatory Cytokines**: Elevated levels of inflammatory cytokines, such as TNF-alpha and IL-6, have been implicated in promoting vascular calcification and thrombosis.
5. **Oxidative Stress**: Increased oxidative stress in ESRD patients can further promote calcification and cellular injury in the vasculature.

The condition is multifactorial, integrating abnormalities in calcium/phosphate metabolism, vascular biology, and inflammatory pathways. Treatment often involves managing the underlying renal disease and addressing metabolic and inflammatory contributors to halt the progression of vascular calcification and tissue necrosis.
Treatment: The treatment of calciphylaxis requires a multidisciplinary approach, using the knowledge of nephrologists, plastic surgeons, dermatologists, and wound care specialists working together to manage the disease and its outcomes. The key to treating calciphylaxis is prevention via rigorous control of phosphate and calcium balance and management of risk factors in patients who have increased chances of developing calciphylaxis. There is no specific treatment. Most treatment recommendations lack significant data, and none are internationally recognized as the standard of care. It is generally accepted to apply a multi-pronged approach to each patient.
Compassionate Use Treatment: Calciphylaxis is a rare and serious disease characterized by calcification of small blood vessels in the fat and skin, leading to painful skin ulcers and infections. Given its severity and the limited availability of definitive treatment protocols, various compassionate use, off-label, and experimental treatments are sometimes considered.

### Compassionate Use Treatments:
1. **Sodium Thiosulfate:** Often used compassionately to reduce calcium deposits and improve wound healing.
2. **Warfarin Termination:** Stopping warfarin can sometimes help, as it may be implicated in worsening calciphylaxis.

### Off-Label Treatments:
1. **Sodium Thiosulfate:** Although not specifically approved for calciphylaxis, it is widely used off-label.
2. **Cinacalcet:** Utilized off-label to control hyperparathyroidism, which is often present in patients with calciphylaxis.
3. **Bisphosphonates (e.g., Pamidronate):** Used off-label for their potential to inhibit the calcification process.

### Experimental Treatments:
1. **Hyperbaric Oxygen Therapy:** Some case studies suggest it might improve wound healing through enhanced oxygen delivery to tissues.
2. **Novel agents (e.g., SNF472):** Currently under investigation for their potential to inhibit vascular calcification.
3. **Vitamin K:** There is ongoing exploration into high-dose Vitamin K to reverse or halt calcification.

The treatment approach often involves a combination of these methods tailored to the individual’s specific symptoms and underlying conditions.
Lifestyle Recommendations: Calciphylaxis is a serious, rare condition involving calcification of blood vessels, which can lead to painful skin ulcers and potentially deadly infections. It's often seen in patients with kidney disease but can occur in others as well.

### Lifestyle Recommendations for Calciphylaxis:

1. **Diet Management**:
- Follow a diet low in calcium and phosphorus. This often means restricting dairy products, certain vegetables, nuts, and whole grains.
- Limit foods high in potassium if you have kidney disease.

2. **Hydration**:
- Maintain adequate hydration but follow any fluid restrictions advised by your healthcare provider.

3. **Skin Care**:
- Practice good wound care and hygiene to prevent infections.
- Regularly moisturize skin to prevent cracking and ulcers.

4. **Avoid Trauma**:
- Minimize physical trauma to the skin by wearing protective clothing and avoiding activities that may cause skin injury.

5. **Medical Adherence**:
- Adhere strictly to prescribed medications and treatments, including those for managing underlying conditions like kidney disease and diabetes.

6. **Regular Monitoring**:
- Regular follow-up with healthcare providers to monitor and adjust treatment plans.

7. **Exercise**:
- Engage in gentle, low-impact exercise as recommended by a healthcare provider to improve blood circulation without causing skin trauma.

8. **Stop Smoking**:
- Quit smoking as it can further impair blood circulation.

Maintaining a consistent and closely monitored lifestyle can help manage symptoms and improve the quality of life for individuals with calciphylaxis.
Medication: For calciphylaxis, a rare and serious condition often seen in patients with end-stage renal disease, the main medications used include sodium thiosulfate, which helps to dissolve calcium deposits, and warfarin to manage blood clotting. Other treatments may involve antibiotics to prevent or treat infections and pain management. Avoiding calcium and vitamin D supplements is also recommended. Collaboration with a healthcare provider is crucial to tailor the treatment approach.
Repurposable Drugs: Calciphylaxis, also known as calcific uremic arteriolopathy, is a serious and rare condition typically affecting patients with end-stage renal disease. It involves the calcification of small blood vessels in the skin and fat, leading to painful skin ulcers and high mortality. Several medications initially developed for other conditions have shown potential in treating calciphylaxis:

1. **Sodium Thiosulfate**: Originally used to treat cyanide poisoning, it has shown benefits in decreasing vascular calcification due to its antioxidant properties and ability to solubilize calcium deposits.

2. **Cinacalcet**: A calcimimetic agent used to treat secondary hyperparathyroidism in dialysis patients, it can help manage the calcium-phosphorus balance.

3. **Bisphosphonates**: Drugs like pamidronate and etidronate, initially for osteoporosis, may reduce vascular calcification due to their ability to inhibit bone resorption.

4. **Sevelamer**: A phosphate binder that helps manage hyperphosphatemia in chronic kidney disease, potentially reducing calcification.

5. **Warfarin**: Although there are mixed reviews about its efficacy, in some cases, altering coagulation pathways may be considered.

Always consult healthcare providers for appropriate diagnosis and treatment options tailored to individual cases.
Metabolites: Calciphylaxis, also known as calcific uremic arteriolopathy, is a serious, rare condition characterized by the calcification of small blood vessels, leading to skin necrosis and deep tissue ischemia. The primary metabolites associated with calciphylaxis include calcium and phosphorus, which tend to be elevated in patients due to dysregulated mineral metabolism, often seen in individuals with end-stage renal disease (ESRD) on dialysis. Imbalances in these metabolites contribute to the vascular calcification and subsequent tissue damage seen in the disease. Other relevant biochemical markers may include increased levels of parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23).
Nutraceuticals: There is no established evidence that nutraceuticals can effectively treat or manage calciphylaxis. Calciphylaxis is a serious and potentially life-threatening condition often seen in patients with end-stage renal disease or those on dialysis. It involves calcification and thrombosis of small blood vessels in the skin and subcutaneous tissues, leading to painful skin ulcers and necrosis.

The primary treatments focus on managing pain, wound care, reducing calcium and phosphate levels, and addressing any underlying conditions. Such treatments might include sodium thiosulfate, bisphosphonates, or parathyroidectomy. Consulting with a healthcare provider is crucial for proper diagnosis and treatment.
Peptides: Calciphylaxis is a serious and rare condition characterized by the calcification of small blood vessels in the fat and skin tissues, leading to painful skin ulcers and potentially life-threatening infections. The role of peptides in calciphylaxis is not well-defined, but they are not commonly used in its treatment. Treatment typically involves addressing underlying kidney disease, managing electrolyte imbalances, and wound care. Nanotechnology (nan) is not currently a standard treatment for calciphylaxis, though ongoing research may explore its potential in wound healing and drug delivery systems in the future.